RxDoctor Payments Data

Sameh Shenouda, MD

General Practice · Panorama City, CANPI 1487936902

Payments from drug & device makers

$3,046in general payments, 2019–2025

Across 123 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$868
  • AstraZeneca$509
  • Boehringer Ingelheim$384
  • Lilly USA, LLC$354
  • Ironwood Pharmaceuticals, Inc$214
  • Sanofi-aventis U.S. LLC$171
  • plus $546 from 9 others

What the payments were for

  • Food & beverage$3,046100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,046 in reported general payments places this provider in the 90th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$79,550
Medicare patients
77
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin280$261,370
OzempicSemaglutide71$77,217
JanuviaSitagliptin Phosphate76$58,308
LinzessLinaclotide71$47,546
FarxigaDapagliflozin Propanediol61$46,946
EliquisApixaban53$45,581
Diclofenac Sodium95$42,600
TradjentaLinagliptin57$40,812
MounjaroTirzepatide36$36,400
MyrbetriqMirabegron30$26,564
RybelsusSemaglutide18$21,035
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog38$16,303
DapagliflozinDapagliflozin Propanediol20$14,982
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$12,434
XareltoRivaroxaban14$11,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$384$302,182337 claims
Novo NordiskOzempic, Rybelsus$868$98,25289 claims
MerckJanuvia, Janumet$22$68,58193 claims
AbbVieLinzess$39$47,54671 claims
Lilly USA, LLCMounjaro, Trulicity$354$47,43148 claims
AstraZenecaFarxiga$509$46,94661 claims
Astellas Pharma US IncMyrbetriq$68$26,56430 claims
Sanofi-aventis U.S. LLCLantus$171$2,66933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 12,963 general practice providers in California.

Other general practice in Panorama City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →